Barr/DuPont
Executive Summary
Barr's agreement with DuPont to copromote five proprietary Barr products will continue with Bristol-Myers Squibb, the company says. Bristol told analysts last week, while discussing its $7.8 bil. DuPont acquisition, that it had not yet determined whether those products would be transferred with the acquisition or returned to Barr (1"The Pink Sheet" June 11, p. 3)